Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VIRIDIAN THERAPEUTICS ORS INC
VRDN | US
13.73
USD-0.50
-3.51%
VRDN | US
About VIRIDIAN THERAPEUTICS ORS INC
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
13.73
Open
14.25
High
14.48
Low
13.56
Viridian Therapeutics Inc. a biotechnology company discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001 a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003 a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004 a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics Inc. and changed its name to Viridian Therapeutics Inc. in January 2021. Viridian Therapeutics Inc. is headquartered in Waltham Massachusetts.
View LessVRDN | US
Risk
144.9
Sharpe
-0.05
Luna's Score
37/100
Recommendation
Sell
Luna says (VRDN | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
28.8%1 month
144.9%3 months
91.0%6 months
73.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
5.62
Debt to equity
0.04
Debt to assets
0.04
Ent. to EBITDA
-3.18
Ent. to rev.
5.21K
PEG
-
Other Fundamentals
EBITDA
-250.21M
MarketCap
1.05B
MarketCap(USD)
1.05B
Div. yield
-
Op. margin
-100.26K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-53.97
Short ratio
3.80
Short perc.
15.18
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.91
Range1M
15.26
Range3M
20.87
Volumes: Market Activity
Rel. volume
0.31
Price X volume
14.40M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.18 | - | Cheaper |
| Ent. to Revenue | 5,214.27 | - | Expensive |
| PE Ratio | - | 41.03 | - |
| Price to Book | 5.62 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 90.98 | - | Riskier |
| Debt to Equity | 0.04 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 1.05B | - | Emerging |
